Europe
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.
One of the big stories this week that even momentarily eclipsed COVID-19, was the landmark transplant of a genetically modified pig heart into a human male with terminal heart disease. For that and more research stories, read on.
Imcyse’s peptides work by priming cytolytic T cells to recognize and destroy those immune cells attacking the pancreas beta cells.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
NRx is seeking $185 million in damages and claims that Relief has breached the collaboration agreement established in 2020 regarding the development of the COVID-19 drug, aviptadil.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.
PRESS RELEASES